

Disclosure pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 – 8th Interim Announcement

In the period from February 20, 2023 up to and including February 24, 2023, PharmaSGP Holding SE bought back a total of 461 shares of PharmaSGP Holding SE under the share buyback program; on January 3, 2023, PharmaSGP Holding SE disclosed pursuant to Art. 2 Sec. 1 of the Commission Delegated Regulation (EU) No 2016/1052 the beginning of the share buyback on January 4, 2023.

The overall volume of the shares bought back daily in the period from February 20, 2023 up to and including February 24, 2023 and the daily volume-weighted average stock market prices of the shares are as follows:

Date	Aggregate volume	Weighted average price (EUR)
February 20, 2023	35	25.2000
February 21, 2023	126	25.3000
February 22, 2023	150	25.7000
February 23, 2023	150	25.9000
February 24, 2023	-	-
In total	461	25.6178

The total number of shares which have been bought back under the buyback program from January 4, 2023 up to and including February 24, 2023 thus amounts to 3184 shares.

The purchase of the PharmaSGP Holding SE shares was carried out by a bank commissioned by PharmaSGP Holding SE and exclusively via the Frankfurt Stock Exchange (XETRA trading).

More detailed information pursuant to Art. 5 Sec. 1 lit. b) and Sec. 3 of the Regulation (EU) No 596/2014 in conjunction with Art. 2 Sec. 2 and Sec. 3 of the Commission Delegated Regulation (EU) No 2016/1052 is available on the internet at <u>https://ir.pharmasgp.com</u> at share buyback 2023.

Gräfelfing, February 27, 2023

PharmaSGP Holding SE The Management Board